Nanoparticles of lipid monolayer shell and biodegradable polymer core for controlled release of paclitaxel: Effects of surfactants on particles size, characteristics and in vitro performance

International Journal of Pharmaceutics

Volumn 395, Issue 1-2, 2010, Pages 243-250

  Liu, Yutao ^a   Pan, Jie ^a   Feng, Si Shen ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

Anticancer drug delivery; Cancer nanotechnology; DLPC; Nanomedicine; Nanoparticle technology; PLGA

Indexed keywords

1,2 DILAUROYLPHOSPHATIDYLOCHOLINE; EMULSIFYING AGENT; NANOPARTICLE; PACLITAXEL; PHOSPHATIDYLCHOLINE; PHOSPHOLIPID; POLYGLACTIN; POLYMER; POLYVINYL ALCOHOL; SURFACTANT; UNCLASSIFIED DRUG; 1,2-DIDODECANOYL-GLYCERO-3-PHOSPHOCHOLINE; ANTINEOPLASTIC AGENT; DELAYED RELEASE FORMULATION; DRUG CARRIER; LACTIC ACID; PHOSPHATIDYLGLYCEROL; POLYGLYCOLIC ACID; POLYLACTIC ACID-POLYGLYCOLIC ACID COPOLYMER;

ARTICLE; BIODEGRADABILITY; CELL STRAIN MCF 7; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; CYTOTOXICITY; DRUG RELEASE; EMULSION; ENCAPSULATION; EVAPORATION; EXTRACTION; FIELD EMISSION SCANNING ELECTRON MICROSCOPY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IN VITRO STUDY; LIGHT SCATTERING; LIPID MONOLAYER; PARTICLE SIZE; PRIORITY JOURNAL; SURFACE PROPERTY; X RAY PHOTOELECTRON SPECTROSCOPY; BREAST TUMOR; CELL SURVIVAL; CHEMISTRY; DELAYED RELEASE FORMULATION; DOSE RESPONSE; DRUG EFFECTS; DRUG FORMULATION; FEMALE; IC50; KINETICS; LIGHT; MEDICINAL CHEMISTRY; METABOLISM; PATHOLOGY; PHARMACEUTICS; PROCEDURES; RADIATION SCATTERING; SCANNING ELECTRON MICROSCOPY; SOLUBILITY; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL SURVIVAL; CHEMISTRY, PHARMACEUTICAL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DELAYED-ACTION PREPARATIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG CARRIERS; DRUG COMPOUNDING; FEMALE; HUMANS; INHIBITORY CONCENTRATION 50; KINETICS; LACTIC ACID; LIGHT; MICROSCOPY, ELECTRON, SCANNING; NANOPARTICLES; PACLITAXEL; PARTICLE SIZE; PHOSPHATIDYLGLYCEROLS; PHOTOELECTRON SPECTROSCOPY; POLYGLYCOLIC ACID; POLYVINYL ALCOHOL; SCATTERING, RADIATION; SOLUBILITY; SURFACE PROPERTIES; SURFACE-ACTIVE AGENTS; TECHNOLOGY, PHARMACEUTICAL;

EID: 77954310123     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2010.05.008     Document Type: Article

References (44)

1. Chan J.M., Zhang L.F., Yuet K.P., Liao G., Rhee J.-W., Langer R., Farokhzad O.C. PLGA-lecithin-PEG core-shell nanoparticles for controlled drug delivery. Biomaterials 2009, 30:1627-1634.
2. Chithrani B.D., Ghazani A.A., Chan W.C.W. Determining the size and shape dependence of gold nanoparticle uptake into mammalian cells. Nano Lett. 2006, 6:662-668.
3. Cho K., Wang X., Nie S.M., Chen Z., Shin D.M. Therapeutic nanoparticles for drug delivery in cancer. Clin. Cancer Res. 2008, 14:1310-1316.
4. De Miguel I., Imbertie L., Rieumajou V., Major M., Kravtzoff R., Betbeder D. Proofs of the structure of lipid coated nanoparticles (SMBV) used as drug carriers. Pharm. Res. 2000, 17:817-824.
5. Decuzzi P., Ferrari M. The role of specific and non-specific interactions in receptor-mediated endocytosis of nanoparticles. Biomaterials 2007, 28:2915-2922.
6. Dong Y.C., Feng S.S. In vitro and in vivo evaluation of methoxy polyethylene glycol-polylactide (MPEG-PLA) nanoparticles for small-molecule drug chemotherapy. Biomaterials 2007, 28:4154-4160.
7. Duncan R. Polymer conjugates as anticancer nanomedicines. Nat. Rev. Cancer 2006, 6:688-701.
8. Evora C., Soriano I., Rogers R.A., Shakesheff K.M., Hanes J., Langer R. Relating the phagocytosis of microparticles by alveolar macrophages to surface chemistry: the effect of 1,2-dipalmitoylphosphatidylcholine. J. Control. Release 1998, 51:143-152.
9. Farokhzad O.C., Langer R. Impact of nanotechnology on drug delivery. ACS Nano 2009, 3:16-20.
10. Feng S.S., Chien S. Chemotherapeutic engineering: application and further development of chemical engineering principles for chemotherapy of cancer and other diseases. Chem. Eng. Sci. 2003, 58:4087-4114.
11. ®) from nanospheres of biodegradable polymers. J. Control. Release 2001, 71:53-69.
12. ®). Mater. Sci. Eng. C 2002, 20:85-92.
13. Feng S.S., Mu L., Khin Y.W., Huang G.F. Nanoparticles of biodegradable polymers for clinical administration of paclitaxel. Curr. Med. Chem. 2004, 11:413-424.
14. Feng S.S., Zhao L.Y., Zhang Z.P., Bhakta G., Khin Y.W., Dong Y.C., Chien S. Chemotherapeutic engineering: vitamin E TPGS-emulsified nanoparticles of biodegradable polymers realized sustainable paclitaxel chemotherapy for 168h in vivo. Chem. Eng. Sci. 2007, 62:6641-6648.
15. Ferrari M. Cancer nanotechnology: opportunities and challenges. Nat. Rev. Cancer 2005, 5:161-171.
16. Garti N. What can nature offer from an emulsifier point of view: trends and progress?. Colloid Surf. A 1999, 152:125-146.
17. Gradishar W.J., Tjulandin S., Davidson N. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J. Clin. Oncol. 2005, 23:7794-7803.
18. Ishii F., Nii T. Properties of various phospholipid mixtures as emulsifiers or dispersing agents in nanoparticle drug carrier preparations. Colloid Surf. B 2005, 41:257-262.
19. Jemal A., Siegel R., Ward E., Hao Y.P., Xu J.Q., Murray T., Thun M.J. Cancer statistics, 2008. CA Cancer J. Clin. 2008, 58:71-96.
20. Khin Y.W., Feng S.S. Effects of particle size and surface coating on cellular uptake of polymeric nanoparticles for oral delivery of anticancer drugs. Biomaterials 2005, 26:2713-2722.
21. Khin Y.W., Feng S.S. In vitro and in vivo studies on vitamin E TPGS-emulsified poly(d,l-lactic-co-glycolic acid) nanoparticles for paclitaxel formulation. Biomaterials 2006, 27:2285-2291.
22. Kim T.Y., Kim D.W., Chung J.Y., Shin S.G., Kim S.C., Heo D.S., Kim N.K., Bang Y.J. Phase I and pharmacokinetic study of Genexol-PM, a cremophor-free, polymeric micelle-formulated paclitaxel, in patients with advanced malignancies. Clin. Cancer Res. 2004, 10:3708-3716.
23. Li Y.Q., Wong H.L., Shuhendler A.J., Rauth A.M., Wu X.Y. Molecular interactions, internal structure and drug release kinetics of rationally developed polymer-lipid hybrid nanoparticles. J. Control. Release 2008, 128:60-70.
24. Lodish H., Berk A., Zipursky L., Matsudaira P. Molecular Cell Biology 2004, W. H. Freeman and Co. 4th ed.
25. Makino K., Yamada T., Kimura M., Oka T., Ohshima H., Kondo T. Temperature- and ionic strength-induced conformational changes in the lipid head group region of liposomes as suggested by zeta potential data. Biophys. Chem. 1991, 41:175-183.
26. Mu L., Feng S.S. Vitamin E TPGS used as emulsifier in the solvent extraction/evaporation technique for fabrication of polymeric nanospheres for controlled release of paclitaxel. J. Control. Release 2002, 80:129-144.
27. Nii T., Ishii F. Properties of various phosphatidylcholines as emulsifiers or dispersing agents in microparticle preparations for drug carriers. Colloid Surf. B 2004, 39:57-63.
28. Pan J., Feng S.S. Targeted delivery of paclitaxel using folate-decorated poly(lactide)-vitamin E TPGS nanoparticles. Biomaterials 2008, 29:2663-2672.
29. Patino J.M.R., Caro A.L., Nino M.R.R., Mackie A.R., Gunning A.P., Morris V.J. Some implications of nanoscience in food dispersion formulations containing phospholipids as emulsifiers. Food Chem. 2007, 102:532-541.
30. Rai S., Paliwal R., Gupta P.N., Khatri K., Goyal A.K., Vaidya B., Vyas S.P. Solid lipid nanoparticles (SLNs) as a rising tool in drug delivery science: one step up in nanotechnology. Curr. Nanosci. 2008, 4:30-44.
31. Ruan G., Feng S.S. Preparation and characterizations of PLA-PEG-PLA microspheres for controlled release of paclitaxel. Biomaterials 2003, 24:5037-5044.
32. Sun B.F., Ranganathan B., Feng S.S. Multi-functional poly(d,l-lactide-co-glycolide)/montmorillonite (PLGA/MMT) nanoparticles decorated by Trastuzumab for targeted chemotherapy of breast cancer. Biomaterials 2008, 29:475-486.
33. Thevenot J., Troutier A.L., David L., Delair T., Ladaviere C. Steric stabilization of lipid/polymer particle assemblies by poly(ethylene glycol)-lipids. Biomacromolecules 2007, 8:3651-3660.
34. Tong R., Cheng J.J. Anticancer polymeric nanomedicines. Polym. Rev. 2007, 47:3450-3481.
35. Torchilin V.P. Recent advances with liposomes as pharmaceutical carriers. Nat. Rev. Drug Discov. 2005, 4:145-160.
36. Wong H.L., Bendayan R., Rauth A.M., Wu X.Y. Simultaneous delivery of doxorubicin and GG918 (Elacridar) by new polymer-lipid hybrid nanoparticles (PLN) for enhanced treatment of multidrug-resistant breast cancer. J. Control. Release 2006, 116:275-284.
37. Wong H.L., Bendayan R., Rauth A.M., Xue H.Y., Babakhanian K., Wu X.Y. A mechanistic study of enhanced doxorubicin uptake and retention in multidrug resistant breastcancer cells using a polymer-lipid hybrid nanoparticle system. J. Pharmacol. Exp. Ther. 2006, 317:1372-1381.
38. Wong H.L., Rauth A.M., Bendayan R., Wu X.Y. In vivo evaluation of a new polymer-lipid hybrid nanoparticle (PLN) formulation of doxorubicin in a murine solid tumor model. Eur. J. Pharm. Biopharm. 2007, 65:300-308.
39. Zauner W., Farrow N.A., Haines A.M.R. In vitro uptake of polystyrene microspheres: effect of particle size, cell line and cell density. J. Control. Release 2001, 71:39-51.
40. Zhang Z.P., Feng S.S. The drug encapsulation efficiency, in vitro drug release, cellular uptake and cytotoxicity of paclitaxel-loaded poly(lactide)-tocopheryl polyethylene glycol succinate nanoparticles. Biomaterials 2006, 27:4025-4033.
41. Zhang L.F., Chan J.M., Gu F.X., Rhee J.-W., Wang A.Z., Radovic-Moreno A.F., Alexis F., Langer R., Farokhzad O.C. Self-assembled lipid-polymer hybrid nanoparticles: a robust drug delivery platform. ACS Nano 2008, 2:1696-1702.
42. Zhang L.F., Gu F.X., Chan J.M., Wang A.Z., Langer R., Farokhzad O.C. Nanoparticles in medicine: therapeutic applications and developments. Clin. Pharmacol. Ther. 2008, 83:761-769.
43. Zhang Z.P., Lee S.H., Gan C.W., Feng S.S. In vitro and in vivo investigation on PLA-TPGS nanoparticles for controlled and sustained small molecule chemotherapy. Pharm. Res. 2008, 25:1925-1935.
44. Zhen X.M., Martin G.P., Marriott C. The controlled delivery of drugs to the lung. Int. J. Pharm. 1995, 124:149-164.